Alzheimer’s disease drugs in trial phase III by mechanism of action 2024
As of January 1, 2024, a combined 65 percent of Alzheimer’s disease drugs in clinical phase III of development were disease-modifying therapies, of which 37 percent were small molecule therapies. This statistic illustrates Alzheimer’s disease drugs in phase III of development worldwide, by mechanism of action.